Summary

This article presents the results of a retrospective study that demonstrated a trend toward additional clinical improvement when spironolactone was added to ambrisentan for the treatment of patients with pulmonary arterial hypertension. This study analyzed data from patients in the double-blind, placebo-controlled Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension studies [ARIES-1 and −2; Galiè N et al. Circulation 2008].